Canaccord Genuity Group Cuts Neurogene (NASDAQ:NGNE) Price Target to $166.00

Neurogene (NASDAQ:NGNE) had its price target lowered by Canaccord Genuity Group from $180.00 to $166.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently issued reports on NGNE. Guggenheim upped their price target on shares of Neurogene from $69.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright dropped their price objective on shares of Neurogene from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. Rodman & Renshaw started coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 target price on the stock. Finally, UBS Group set a $70.00 price target on shares of Neurogene in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Neurogene Price Performance

NASDAQ:NGNE opened at $36.14 on Wednesday. The company has a market cap of $723.16 million, a price-to-earnings ratio of -7.18 and a beta of 1.70. Neurogene has a 1 year low of $15.93 and a 1 year high of $43.66. The stock’s 50 day simple moving average is $34.11 and its two-hundred day simple moving average is $26.90.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). As a group, analysts anticipate that Neurogene will post -5.55 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Christine Mikail Cvijic sold 4,200 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the sale, the chief financial officer owned 84,040 shares in the company, valued at approximately $3,036,365.20. This represents a 4.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 9,600 shares of company stock worth $339,932. Corporate insiders own 11.68% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after acquiring an additional 1,059 shares during the period. Bank of America Corp DE boosted its stake in shares of Neurogene by 81.6% during the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after purchasing an additional 42,880 shares during the period. BNP Paribas Financial Markets grew its holdings in Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in Neurogene during the 3rd quarter valued at about $187,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Neurogene in the 3rd quarter worth about $12,114,000. Institutional investors own 52.37% of the company’s stock.

Trending Headlines about Neurogene

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $65 price target while raising its FY2027 EPS forecast to a loss of $4.99 per share from a projected loss of $5.92. The firm also lifted its estimates for the first three quarters of 2027, indicating expectations for reduced losses over time.
• Positive Sentiment: HC Wainwright increased its Q4 2026 EPS estimate to a loss of $1.20 from $1.37 and raised its Q1–Q4 2027 estimates to losses of $1.22, $1.24, $1.26 and $1.27, respectively. These revisions suggest improving operating expectations beyond 2026.
• Positive Sentiment: Canaccord Genuity lowered its price target to $166, but the revised target remains substantially above Neurogene’s recent trading level, potentially reinforcing the stock’s significant upside narrative. Canaccord Genuity Group Lowers Neurogene Price Target
• Neutral Sentiment: HC Wainwright lowered its FY2026 EPS estimate modestly to a loss of $5.44 from $5.39 and trimmed its Q3 2026 estimate to a loss of $1.36 from $1.34. Neurogene is still expected to remain unprofitable, with consensus full-year EPS at a loss of $5.63.
• Negative Sentiment: The company’s latest quarterly results missed analyst expectations, reporting a $1.53-per-share loss versus the $1.42 consensus estimate. Continued losses and the absence of current earnings make the stock highly dependent on clinical and development progress.

Neurogene Company Profile

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.